Description de l'entreprise
With a focus on transformative medicines in oncology, rare disease and neuroscience, our vision is to be a leading global mid-size biopharmaceutical company. With the right combination of size and agility, we continue to push ourselves as a business and as individuals to deliver positive change.
Conseil d'administration & Conseil de surveillance
| PDG |
| David Loew |
| Conseil d'administration |
| Yan Moore M.D., Aymeric Le Chatelier, Aidan Murphy Ph.D., Craig Marks, Francois Garnier, Gwenan White, Regis Mulot, Dominique Bery, Alexander McEwan |
| Conseil de surveillance |
| - |
Données de l'entreprise
| Nom: |
Ipsen SA |
| Adresse: |
65, quai Georges Gorse,65, quai Georges Gorse Boulogne-Billancourt 92100 |
| Téléphone: |
+33 1 58 33 50 00 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
https://www.ipsen.com |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
41.52% |
| IPO date: |
01/12/2005 |
Relations avec les investisseurs
| Nom: |
Craig Marks |
| Téléphone IR: |
+44 7584 349 193 |
| IR-Fax: |
- |
| E-mail IR: |
-
|
